Stay updated with breaking news from Ted Myles. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Advancing industry-leading antimyostatin pipeline, comprised of multiple, novel assets with unparalleled selectivity, to treat spinal muscular atrophy and cardiometabolic disorders - Completed...
Rushmie Nofsinger: Good morning. I'm Rushmie Nofsinger, Vice President of Corporate Affairs and Investor Relations at Scholar Rock.
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2023 Earnings Call Transcript November 7, 2023 Rushmie Nofsinger: Good morning. I’m Rushmie Nofsinger, Vice President of Corporate Affairs and Investor Relations at Scholar Rock. Welcome, and thank you for joining us today for our Q3 2023 Business Update Call. This call is audio-only. You can access the slides […]
- Recently presented 36-month apitegromab extension data from Phase 2 TOPAZ trial demonstrate long-term substantial and sustained improvement of motor function and further strengthen conviction in...
- Enrollment of pivotal Phase 3 SAPPHIRE trial evaluating apitegromab on track for completion in 2023 - Upcoming presentations of 36-month apitegromab data from Phase 2 TOPAZ trial at Cure... | May 9, 2023